Information  X 
Enter a valid email address

Martin Currie GblPrt (MNP)

  Print          Annual reports

Tuesday 19 January, 2021

Martin Currie GblPrt

Changes to Investment Management Fee

RNS Number : 2030M
Martin Currie Global Portfolio Tst
19 January 2021

Martin Currie Global Portfolio Trust plc

Legal Entity Identifier: 549300RKB85NFVSTBM94


Changes to Investment Management and Performance Fee Arrangements

1 February 2021


The Board of Martin Currie Global Portfolio Trust plc ("the Company") announces that, following a review, the Company has agreed with Martin Currie Investment Management Limited ("the Investment Manager") that, with effect from 1 February 2021, the performance fee arrangement will be discontinued and the investment management fee amended from 0.4% to 0.5% per annum for the first £300m of the Company's net asset value (excluding income) and from 0.4% to 0.35% for net assets (excluding income) in excess of £300m,. 


The removal of the performance fee results in a simpler and more transparent cost structure and the newly agreed tiered investment management fee contributes to a stable ongoing charge which will progressively reduce as the net asset value grows.


The Board are confident that the new structure will maintain a competitive ongoing charge and contribute to increasing shareholder value.   


For further information, please contact:


Ewan Cameron

For and on behalf of

Martin Currie Investment Management Limited

Company Secretary

0131 229 5252


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t